Jakarta –
Even though the COVID-19 case has slowed down in the country, our Mother should always be vigilant by always implementing health protocols, including getting vaccines.
Until now, the provision of the COVID-19 vaccine in Indonesia has entered the third stage, Mother, aka the booster vaccine, have you received it too? Well, specifically for Sinovac vaccine recipients, there is the latest news from a study held in Singapore.
Bunda, a study in Singapore revealed that recipients of the Sinovac COVID-19 vaccine were five times more likely to experience a severe case of COVID-19 when compared to those who received Pfizer.
The research was conducted on 2.7 million Singaporeans aged 20 years and over who received the complete Sinovac vaccine or two doses of the COVID-19 vaccine from the Chinese pharmaceutical company.
The study published on Tuesday (12/4) analyzed the effectiveness of the Sinovac vaccine for seven weeks in 2021 from October 1 to November 21, when the country was hit by the Delta variant of COVID-19.
Reported from Channel News Asiaa team of infectious disease experts from the National Center for Infectious Diseases (NCID) and the Singapore Ministry of Health (MOH), observed the relatively lower effectiveness of the two vaccines. inactivated Sinovac and Sinopharm viruses against COVID-19 infection when compared with Pfizer-BioNTech and Moderna mRNA vaccines.
Those who received the Sinovac vaccine were 4.59 times more likely to experience severe COVID-19 symptoms when compared to Pfizer-BioNTech vaccine recipients. Sinovac users were also 2.37 times more likely to be infected when compared to those who used the Pfizer-BioNTech vaccine.
Severe illness or symptoms of COVID-19 were defined as patients requiring oxygen supplementation in the hospital, admission to the intensive care unit (ICU), to death.
The report also shows the Moderna vaccine is more effective in preventing severe disease than the Pfizer-BioNTech vaccine.
Those taking Moderna were found to be less than half (0.42) times more likely to have severe COVID-19 than Pfizer-BioNTech recipients, and they were also less likely to become infected.
According to a report from the US Centers for Disease Control and Prevention, the higher effectiveness of the Moderna vaccine is likely due to the higher mRNA content in the COVID-19 vaccine and the longer time interval between injections.
READ THE FULL ARTICLE HERE.
(pri / pri)
–
